Matches in Nanopublications for { ?s ?p "[A total of 209 consecutive patients with stage IV nonsquamous NSCLC with an EGFR (epidermal growth factor receptor) mutation (N = 39), KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation (N = 49), ALK (anaplastic lymphoma receptor tyrosine kinase) gene rearrangement (N = 41), or wild-type for all 3 (triple negative, N = 80) were included.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP204463.RAd6z1qiR8aB3d0aSc692DSH1_POiLI33swIIwmgh694s130_assertion description "[A total of 209 consecutive patients with stage IV nonsquamous NSCLC with an EGFR (epidermal growth factor receptor) mutation (N = 39), KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation (N = 49), ALK (anaplastic lymphoma receptor tyrosine kinase) gene rearrangement (N = 41), or wild-type for all 3 (triple negative, N = 80) were included.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP204463.RAd6z1qiR8aB3d0aSc692DSH1_POiLI33swIIwmgh694s130_provenance.
- assertion description "[A total of 209 consecutive patients with stage IV nonsquamous NSCLC with an EGFR (epidermal growth factor receptor) mutation (N = 39), KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation (N = 49), ALK (anaplastic lymphoma receptor tyrosine kinase) gene rearrangement (N = 41), or wild-type for all 3 (triple negative, N = 80) were included.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP956390.RAUBXyo_FHx2nj_jUVHPKuPvVJvuVaDjboHfFkTcdqElI130_assertion description "[A total of 209 consecutive patients with stage IV nonsquamous NSCLC with an EGFR (epidermal growth factor receptor) mutation (N = 39), KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation (N = 49), ALK (anaplastic lymphoma receptor tyrosine kinase) gene rearrangement (N = 41), or wild-type for all 3 (triple negative, N = 80) were included.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP956390.RAUBXyo_FHx2nj_jUVHPKuPvVJvuVaDjboHfFkTcdqElI130_provenance.
- NP956393.RAD0pgjU8Gk1UI1JZ-Vj8BygsST22eZTw9VUvYUwK0wEA130_assertion description "[A total of 209 consecutive patients with stage IV nonsquamous NSCLC with an EGFR (epidermal growth factor receptor) mutation (N = 39), KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation (N = 49), ALK (anaplastic lymphoma receptor tyrosine kinase) gene rearrangement (N = 41), or wild-type for all 3 (triple negative, N = 80) were included.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP956393.RAD0pgjU8Gk1UI1JZ-Vj8BygsST22eZTw9VUvYUwK0wEA130_provenance.
- NP956396.RAjUwDW5yzAZUcFsBeQRCUFkDeRUABGMYYZKztBghB4mY130_assertion description "[A total of 209 consecutive patients with stage IV nonsquamous NSCLC with an EGFR (epidermal growth factor receptor) mutation (N = 39), KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation (N = 49), ALK (anaplastic lymphoma receptor tyrosine kinase) gene rearrangement (N = 41), or wild-type for all 3 (triple negative, N = 80) were included.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP956396.RAjUwDW5yzAZUcFsBeQRCUFkDeRUABGMYYZKztBghB4mY130_provenance.
- NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_assertion description "[A total of 209 consecutive patients with stage IV nonsquamous NSCLC with an EGFR (epidermal growth factor receptor) mutation (N = 39), KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation (N = 49), ALK (anaplastic lymphoma receptor tyrosine kinase) gene rearrangement (N = 41), or wild-type for all 3 (triple negative, N = 80) were included.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_provenance.
- NP956391.RAxA8x8VIE6enNuTXg_6Hwt8oHdq53tUpR1qgCzgKzXmQ130_assertion description "[A total of 209 consecutive patients with stage IV nonsquamous NSCLC with an EGFR (epidermal growth factor receptor) mutation (N = 39), KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation (N = 49), ALK (anaplastic lymphoma receptor tyrosine kinase) gene rearrangement (N = 41), or wild-type for all 3 (triple negative, N = 80) were included.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP956391.RAxA8x8VIE6enNuTXg_6Hwt8oHdq53tUpR1qgCzgKzXmQ130_provenance.